Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Nuclear Receptor ROR-Gamma Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Nuclear Receptor ROR-Gamma Market Status and Forecast (2016-2027)
      • 1.3.2 Global Nuclear Receptor ROR-Gamma Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Nuclear Receptor ROR-Gamma Supply by Company

    • 2.1 Global Nuclear Receptor ROR-Gamma Sales Volume by Company
    • 2.2 Global Nuclear Receptor ROR-Gamma Sales Value by Company
    • 2.3 Global Nuclear Receptor ROR-Gamma Price by Company
    • 2.4 Nuclear Receptor ROR-Gamma Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Nuclear Receptor ROR-Gamma Market Status by Category

    • 3.1 Nuclear Receptor ROR-Gamma Category Introduction
      • 3.1.1 VPR-66
      • 3.1.2 INV-17
      • 3.1.3 GSK-2981278
      • 3.1.4 BBI-6000
      • 3.1.5 Others
    • 3.2 Global Nuclear Receptor ROR-Gamma Market by Category
      • 3.2.1 Global Nuclear Receptor ROR-Gamma Sales Volume by Category (2016-2021)
      • 3.2.2 Global Nuclear Receptor ROR-Gamma Sales Value by Category (2016-2021)
      • 3.2.3 Global Nuclear Receptor ROR-Gamma Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Nuclear Receptor ROR-Gamma Market Status by End User/Segment

    • 4.1 Nuclear Receptor ROR-Gamma Segment by End User/Segment
      • 4.1.1 Hospital
      • 4.1.2 Clinic
      • 4.1.3 Others
    • 4.2 Global Nuclear Receptor ROR-Gamma Market by End User/Segment
      • 4.2.1 Global Nuclear Receptor ROR-Gamma Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Nuclear Receptor ROR-Gamma Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Nuclear Receptor ROR-Gamma Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Nuclear Receptor ROR-Gamma Market Status by Region

    • 5.1 Global Nuclear Receptor ROR-Gamma Market by Region
      • 5.1.1 Global Nuclear Receptor ROR-Gamma Sales Volume by Region
      • 5.1.2 Global Nuclear Receptor ROR-Gamma Sales Value by Region
    • 5.2 North America Nuclear Receptor ROR-Gamma Market Status
    • 5.3 Europe Nuclear Receptor ROR-Gamma Market Status
    • 5.4 Asia Pacific Nuclear Receptor ROR-Gamma Market Status
    • 5.5 Central & South America Nuclear Receptor ROR-Gamma Market Status
    • 5.6 Middle East & Africa Nuclear Receptor ROR-Gamma Market Status

    6 North America Nuclear Receptor ROR-Gamma Market Status

    • 6.1 North America Nuclear Receptor ROR-Gamma Market by Country
      • 6.1.1 North America Nuclear Receptor ROR-Gamma Sales Volume by Country (2016-2021)
      • 6.1.2 North America Nuclear Receptor ROR-Gamma Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Nuclear Receptor ROR-Gamma Market Status

    • 7.1 Europe Nuclear Receptor ROR-Gamma Market by Country
      • 7.1.1 Europe Nuclear Receptor ROR-Gamma Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Nuclear Receptor ROR-Gamma Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Nuclear Receptor ROR-Gamma Market Status

    • 8.1 Asia Pacific Nuclear Receptor ROR-Gamma Market by Country
      • 8.1.1 Asia Pacific Nuclear Receptor ROR-Gamma Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Nuclear Receptor ROR-Gamma Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Nuclear Receptor ROR-Gamma Market Status

    • 9.1 Central & South America Nuclear Receptor ROR-Gamma Market by Country
      • 9.1.1 Central & South America Nuclear Receptor ROR-Gamma Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Nuclear Receptor ROR-Gamma Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Nuclear Receptor ROR-Gamma Market Status

    • 10.1 Middle East & Africa Nuclear Receptor ROR-Gamma Market by Country
      • 10.1.1 Middle East & Africa Nuclear Receptor ROR-Gamma Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Nuclear Receptor ROR-Gamma Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Nuclear Receptor ROR-Gamma Manufacturing Cost Analysis
    • 11.5 Nuclear Receptor ROR-Gamma Sales Channel and Distributors Analysis
      • 11.5.1 Nuclear Receptor ROR-Gamma Sales Channel
      • 11.5.2 Nuclear Receptor ROR-Gamma Distributors
    • 11.6 Nuclear Receptor ROR-Gamma Downstream Major Buyers

    12 Global Nuclear Receptor ROR-Gamma Market Forecast by Category and by End User/Segment

    • 12.1 Global Nuclear Receptor ROR-Gamma Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Nuclear Receptor ROR-Gamma Forecast by Category
      • 12.2.1 Global Nuclear Receptor ROR-Gamma Sales Volume Forecast by Category
      • 12.2.2 Global Nuclear Receptor ROR-Gamma Sales Value Forecast by Category
      • 12.2.3 Global Nuclear Receptor ROR-Gamma Price Forecast by Category
    • 12.3 Global Nuclear Receptor ROR-Gamma Forecast by End User/Segment
      • 12.3.1 Global Nuclear Receptor ROR-Gamma Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Nuclear Receptor ROR-Gamma Sales Value Forecast by End User/Segment
      • 12.3.3 Global Nuclear Receptor ROR-Gamma Price Forecast by End User/Segment

    13 Global Nuclear Receptor ROR-Gamma Market Forecast by Region/Country

    • 13.1 Global Nuclear Receptor ROR-Gamma Market Forecast by Region (2022-2027)
      • 13.1.1 Global Nuclear Receptor ROR-Gamma Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Nuclear Receptor ROR-Gamma Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 4SC AG
      • 14.1.1 Company Information
      • 14.1.2 Nuclear Receptor ROR-Gamma Product Introduction
      • 14.1.3 4SC AG Nuclear Receptor ROR-Gamma Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Vitae Pharmaceuticals, Inc.
      • 14.2.1 Company Information
      • 14.2.2 Nuclear Receptor ROR-Gamma Product Introduction
      • 14.2.3 Vitae Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Visionary Pharmaceuticals, Inc.
      • 14.3.1 Company Information
      • 14.3.2 Nuclear Receptor ROR-Gamma Product Introduction
      • 14.3.3 Visionary Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Teijin Pharma Limited
      • 14.4.1 Company Information
      • 14.4.2 Nuclear Receptor ROR-Gamma Product Introduction
      • 14.4.3 Teijin Pharma Limited Nuclear Receptor ROR-Gamma Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Reata Pharmaceuticals, Inc.
      • 14.5.1 Company Information
      • 14.5.2 Nuclear Receptor ROR-Gamma Product Introduction
      • 14.5.3 Reata Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Phenex Pharmaceuticals AG
      • 14.6.1 Company Information
      • 14.6.2 Nuclear Receptor ROR-Gamma Product Introduction
      • 14.6.3 Phenex Pharmaceuticals AG Nuclear Receptor ROR-Gamma Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Nuevolution AB
      • 14.7.1 Company Information
      • 14.7.2 Nuclear Receptor ROR-Gamma Product Introduction
      • 14.7.3 Nuevolution AB Nuclear Receptor ROR-Gamma Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Lead Pharma Holding B.V.
      • 14.8.1 Company Information
      • 14.8.2 Nuclear Receptor ROR-Gamma Product Introduction
      • 14.8.3 Lead Pharma Holding B.V. Nuclear Receptor ROR-Gamma Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Karo Bio AB
      • 14.9.1 Company Information
      • 14.9.2 Nuclear Receptor ROR-Gamma Product Introduction
      • 14.9.3 Karo Bio AB Nuclear Receptor ROR-Gamma Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Hanmi Pharmaceuticals, Co. Ltd.
      • 14.10.1 Company Information
      • 14.10.2 Nuclear Receptor ROR-Gamma Product Introduction
      • 14.10.3 Hanmi Pharmaceuticals, Co. Ltd. Nuclear Receptor ROR-Gamma Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 GlaxoSmithKline Plc
    • 14.12 Genfit SA
    • 14.13 Genentech, Inc.
    • 14.14 Celgene Corporation
    • 14.15 Bristol-Myers Squibb Company
    • 14.16 Brickell Biotech, Inc.
    • 14.17 Biogen, Inc.
    • 14.18 Aurigene Discovery Technologies Limited
    • 14.19 Arrien Pharmaceuticals, LLC
    • 14.20 Advinus Therapeutics Ltd.

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Nuclear Receptor ROR-Gamma market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Nuclear Receptor ROR-Gamma market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      VPR-66
      INV-17
      GSK-2981278
      BBI-6000
      Others

      Segmented by End User/Segment
      Hospital
      Clinic
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      4SC AG
      Vitae Pharmaceuticals, Inc.
      Visionary Pharmaceuticals, Inc.
      Teijin Pharma Limited
      Reata Pharmaceuticals, Inc.
      Phenex Pharmaceuticals AG
      Nuevolution AB
      Lead Pharma Holding B.V.
      Karo Bio AB
      Hanmi Pharmaceuticals, Co. Ltd.
      GlaxoSmithKline Plc
      Genfit SA
      Genentech, Inc.
      Celgene Corporation
      Bristol-Myers Squibb Company
      Brickell Biotech, Inc.
      Biogen, Inc.
      Aurigene Discovery Technologies Limited
      Arrien Pharmaceuticals, LLC
      Advinus Therapeutics Ltd.
      Buy now